IL314022A - Methods of treating idiopathic pulmonary fibrosis with deupirfenidone - Google Patents
Methods of treating idiopathic pulmonary fibrosis with deupirfenidoneInfo
- Publication number
- IL314022A IL314022A IL314022A IL31402224A IL314022A IL 314022 A IL314022 A IL 314022A IL 314022 A IL314022 A IL 314022A IL 31402224 A IL31402224 A IL 31402224A IL 314022 A IL314022 A IL 314022A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- lyt
- treatment
- pirfenidone
- tid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296826P | 2022-01-05 | 2022-01-05 | |
| US202263296843P | 2022-01-05 | 2022-01-05 | |
| US202263296818P | 2022-01-05 | 2022-01-05 | |
| US202263326132P | 2022-03-31 | 2022-03-31 | |
| US202263326129P | 2022-03-31 | 2022-03-31 | |
| US202263341269P | 2022-05-12 | 2022-05-12 | |
| US202263341281P | 2022-05-12 | 2022-05-12 | |
| US202263341279P | 2022-05-12 | 2022-05-12 | |
| US202263341828P | 2022-05-13 | 2022-05-13 | |
| US202263352107P | 2022-06-14 | 2022-06-14 | |
| US202263356653P | 2022-06-29 | 2022-06-29 | |
| US202263374362P | 2022-09-01 | 2022-09-01 | |
| US202263403481P | 2022-09-02 | 2022-09-02 | |
| US202263431530P | 2022-12-09 | 2022-12-09 | |
| US202263432208P | 2022-12-13 | 2022-12-13 | |
| PCT/US2023/060185 WO2023133476A1 (en) | 2022-01-05 | 2023-01-05 | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314022A true IL314022A (en) | 2024-08-01 |
Family
ID=87074293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314022A IL314022A (en) | 2022-01-05 | 2023-01-05 | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240358690A1 (https=) |
| EP (1) | EP4460305A4 (https=) |
| JP (1) | JP2025502023A (https=) |
| KR (1) | KR20240131352A (https=) |
| AU (1) | AU2023205787A1 (https=) |
| CA (1) | CA3239301A1 (https=) |
| IL (1) | IL314022A (https=) |
| MX (1) | MX2024008476A (https=) |
| WO (1) | WO2023133476A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025511066A (ja) * | 2022-03-31 | 2025-04-15 | ピュアテック・エル・ワイ・ティ・１００・インコーポレイテッド | デューピルフェニドンにより間質性肺疾患ならびに他の線維化介在性肺疾患及び障害を治療する方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| WO2009035598A1 (en) * | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| EP4603148A3 (en) * | 2018-09-14 | 2025-10-29 | Puretech Lyt 100, Inc. | Deuterium-enriched pirfenidone and methods of use thereof |
| CA3171622A1 (en) * | 2020-03-13 | 2021-09-16 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
-
2023
- 2023-01-05 WO PCT/US2023/060185 patent/WO2023133476A1/en not_active Ceased
- 2023-01-05 AU AU2023205787A patent/AU2023205787A1/en active Pending
- 2023-01-05 KR KR1020247022244A patent/KR20240131352A/ko active Pending
- 2023-01-05 CA CA3239301A patent/CA3239301A1/en active Pending
- 2023-01-05 EP EP23737759.3A patent/EP4460305A4/en active Pending
- 2023-01-05 IL IL314022A patent/IL314022A/en unknown
- 2023-01-05 JP JP2024540710A patent/JP2025502023A/ja active Pending
- 2023-01-05 MX MX2024008476A patent/MX2024008476A/es unknown
-
2024
- 2024-06-28 US US18/758,783 patent/US20240358690A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025502023A (ja) | 2025-01-24 |
| WO2023133476A1 (en) | 2023-07-13 |
| US20240358690A1 (en) | 2024-10-31 |
| EP4460305A1 (en) | 2024-11-13 |
| MX2024008476A (es) | 2024-07-12 |
| EP4460305A4 (en) | 2025-12-31 |
| AU2023205787A1 (en) | 2024-06-13 |
| CA3239301A1 (en) | 2023-07-13 |
| KR20240131352A (ko) | 2024-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cobos et al. | Dermatomyositis: An Update on Diagnosis and Treatment: GA Cobos et al. | |
| KR20220011652A (ko) | 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 | |
| AU2025203171A1 (en) | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis | |
| TW202537625A (zh) | 使用布魯頓酪胺酸激酶抑制劑治療慢性自發性蕁麻疹之方法 | |
| CN110536684A (zh) | 三联组合制剂以及治疗心血管疾病或降低心血管疾病风险的方法 | |
| US20220409620A1 (en) | Reducing immunogenicity to pegloticase | |
| Boettcher et al. | Vericiguat in combination with short‐acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study | |
| US20240358690A1 (en) | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone | |
| US20230210845A1 (en) | Dosing methods for treatment of cardiovascular conditions | |
| US20250249001A1 (en) | Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators | |
| US20250114341A1 (en) | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone | |
| McNicholl et al. | Omalizumab: the evidence for its place in the treatment of allergic asthma | |
| US20250114340A1 (en) | Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone | |
| CN118510510A (zh) | 用氘吡非尼酮治疗特发性肺纤维化的方法 | |
| US20210137903A1 (en) | Anti-androgens for the treatment of prostrate cancer | |
| HK40114519A (zh) | 用氘吡非尼酮治疗特发性肺纤维化的方法 | |
| TW202237078A (zh) | 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物 | |
| DEVELOPM | Drug DeveloPment | |
| US20230381190A1 (en) | Methods and Treatment for Complex Lymphatic Malformations | |
| KR20260056206A (ko) | 국소 분절 사구체경화증을 치료하기 위한 trpc6의 억제제 | |
| TW202535397A (zh) | 給藥方案 | |
| EA051453B1 (ru) | Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина | |
| WO2020144646A1 (en) | Apalutamide dispersed in applesauce for treating prostate cancer | |
| WO2023229605A1 (en) | Methods and treatment for complex lymphatic malformations | |
| No et al. | Clinical trial protocol |